ArticleJournal of molecular histology2026
Tanshinone IIA alleviates chronic endometritis via DRAK2 inhibition to restore mitochondrial function and suppress KDM3A-SLC2A3-driven NETs formation.
Article in Journal of molecular histology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study aimed to investigate the therapeutic potential of Tanshinone IIA (Tan-IIA) in alleviating chronic endometritis (CE), focusing on its role in mitigating mitochondrial dysfunction and suppressing neutrophil extracellular traps (NETs) formation. HEnEpCs were stimulated with lipopolysaccharide (LPS) to establish an inflammatory model. Application of Tan-IIA as a pretreatment was followed by a comprehensive assessment of mitochondrial function, including JC-1 staining, adenosine triphosphate (ATP) content, reactive oxygen species (ROS) levels, and transmission electron microscopy. A co-culture system with human neutrophils was used to evaluate NETs formation. Molecular mechanisms were probed using real-time quantitative PCR (RT-qPCR), Western blot, chromatin immunoprecipitation (ChIP), and immunofluorescence. A rat model of LPS-induced endometritis was used to validate the effects of Tan-IIA on uterine histopathology, NETs formation, and inflammatory cytokine levels. Tan-IIA significantly ameliorated LPS-induced mitochondrial damage, restored membrane potential, reduced ROS production, and increased ATP levels in HEnEpCs. DRAK2 was elevated in CE patient plasma and LPS-stimulated cells, of which overexpression antagonized protective effects mediated by Tan-IIA. Furthermore, Tan-IIA inhibited NETs formation in co-culture systems, an effect mediated through suppression of the lysine demethylase 3A (KDM3A)-histone H3 lysine 9 dimethylation (H3K9me2)-hypoxia-inducible factor 1-alpha (HIF-1A)-solute carrier family 2 member 3 (SLC2A3) epigenetic-metabolic axis. Tan-IIA reduced neutrophil infiltration, NETs formation, and pro-inflammatory cytokine levels to improve endometrial architecture in LPS-induced rats. Tan-IIA attenuates CE progression by targeting DRAK2 to restore mitochondrial function and inhibiting NETs formation via the KDM3A/SLC2A3 pathway, implying Tan-IIA as a promising multi-target agent for CE therapy.
Indexed as
Identifiers
42141237What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.